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Magnesium sulfate (MgSO4) is the most widely used therapy in the clinic to prevent
the progression of preeclampsia, a hypertensive disorder of pregnancy, to eclampsia.
Eclampsia, manifested as unexplained seizures and/or coma during pregnancy or
postpartum, accounts for ∼13% of maternal deaths worldwide. While MgSO4 continues
to be used in the clinic, the mechanisms by which it exerts its protective actions are
not well understood. In this study, we tested the hypothesis that MgSO4 protects
against placental ischemia-induced increases in brain water content and cerebrospinal
fluid cytokines. To test this hypothesis, MgSO4 was administered via mini-osmotic
pump (60mg/day, i.p.) to pregnant and placental ischemic rats, induced by mechanical
reduction of uterine perfusion pressure, from gestational day 14–19. This treatment
regimen of MgSO4 led to therapeutic level of 2.8± 0.6mmol/L Mg in plasma. MgSO4 had
no effect on improving placental ischemia-induced changes in mean arterial pressure,
number of live fetuses, or fetal and placental weight. Placental ischemia increased, while
MgSO4 prevented the increase in water content in the anterior cerebrum. Cytokine and
chemokine levels were measured in the cerebrospinal fluid using a multi-plex assay.
Results demonstrate that cerebrospinal fluid, obtained via the cisterna magna, had
reduced protein, albumin, interleukin (IL)-17A, IL-18, IL-2, eotaxin, fractalkine, interferon
gamma, vascular endothelial growth factor (VEGF), and macrophage inflammatory
protein (MIP)-2 following MgSO4 treatment. These data support the hypothesis that
MgSO4 offers neuroprotection by preventing placental ischemia-induced cerebral edema
and reducing levels of cytokines/chemokines in the cerebrospinal fluid.
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INTRODUCTION
Magnesium sulfate (MgSO4) is the main course of treatment for preeclampsia patients with severe
symptoms and is often used to prevent the progression of the disorder from preeclampsia to
eclampsia. Preeclampsia complicates about 5–8% of pregnancies in the United States (Saftlas et al.,
1990) and close to 20% of African American pregnancies (Mostello et al., 2002). Preeclampsia
is characterized by new-onset hypertension with proteinuria or in the absence of proteinuria,
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low platelet count, renal insufficiency, impaired liver function,
pulmonary edema, or cerebral or visual symptoms manifesting
after the 20th week of gestation (American College of
Obstetricians & Gynecologists and Task Force on Hypertension
in Pregnancy, 2013). Preeclampsia affects multiple organs
including the kidney, liver, and brain. It should be noted that
of all preeclampsia/eclampsia-related deaths, cerebrovascular
events are the cause in ∼40% of cases (MacKay et al., 2001).
Additional evidence that the cerebral vasculature is affected
in preeclampsia is provided by the common manifestations of
neurological symptoms ranging from headaches to seizures (in
the case of eclampsia) (Chakravarty and Chakrabarti, 2002) in
patients. While MgSO4 is a common treatment, early delivery
of the fetus and removal of the placenta is the only method to
reverse the disorder (Sibai et al., 2005; Sibai, 2006). Thus, novel
therapies for the treatment of preeclampsia are needed, and the
mechanisms by which MgSO4 exerts its beneficial effects need to
be elucidated.
The findings of blood-brain barrier (BBB) disruption and
cerebral edema formation using various imaging modalities,
such as MRI and CT scans (Apollon et al., 2000; Demirtas¸
et al., 2005; Aygün et al., 2010) demonstrate that the cerebral
vasculature is affected in preeclampsia patients. Further evidence
of BBB disruption has been provided using an isolated vessel
preparation that showed that plasma from preeclampsia patients
increases cerebral venous permeability (Amburgey et al., 2010;
Schreurs and Cipolla, 2013; Schreurs et al., 2013). While the
BBB regulates the exchange of substances between the blood and
the brain, the blood-cerebrospinal fluid (CSF)-barrier, formed
primarily by choroid plexus epithelial cells (ependymal cells) or
meningothelial cells, regulates the substances exchanged between
the blood and CSF. A recent study from our lab demonstrated
that placental ischemic rats have increased inflammatory
cytokines in the CSF (Warrington, 2015), suggesting that
there is increased blood-CSF-barrier permeability or increased
production and clearance of cytokines from the extracellular
space to the CSF in response to placental ischemia. Whether
MgSO4 has effects on placental ischemia-induced increases in
CSF cytokines or the blood-CSF-barrier permeability is not
known.
We utilized the rat model of placental ischemia, induced by
reducing uterine perfusion pressure (RUPP) to mimic the clinical
condition of preeclampsia. The placental ischemic model has
numerous similar characteristics to preeclampsia patients. For
example, like preeclampsia patients, placental ischemic rats have
increased arterial blood pressure with or without proteinuria
(Alexander et al., 2001). Additionally, placental ischemia leads
to increased circulating and placental levels of inflammatory
cytokines (LaMarca et al., 2005; Gadonski et al., 2006), and
increased anti-angiogenic factors (Gilbert et al., 2007, 2009),
along with similar cerebrovascular changes as preeclampsia
patients. Recent studies have shown marked impairment in
cerebral blood flow autoregulation, increased BBB permeability,
(Warrington et al., 2014) impaired cerebrovascular myogenic
tone, and cerebral edema (Ryan et al., 2011) in response to
placental ischemia. Importantly, a recent study by Johnson
et al. demonstrated increases in BBB permeability and microglial
activation following placental ischemia and high cholesterol to
mimic severe preeclampsia (Johnson et al., 2014). While the
study assessed changes in brain water content in the posterior
cerebrum, there were no reports of the effects of MgSO4
treatment on edema formation in the anterior cerebrum. Thus,
since the placental ischemia model is characterized by edema
in the anterior cerebrum (Warrington et al., 2014, 2015), we
determined whether MgSO4 would improve placental ischemia-
induced cerebral edema in the anterior and posterior cerebrum.
The purpose of this study was to assess whether MgSO4,
administered during the third trimester (from gestational day
14–19), leads to improvements in blood pressure, fetal outcome,
brain water content, blood-CSF-barrier permeability, and CSF
cytokine/chemokine levels following placental ischemia. While a
recent study showed beneficial effects of acute MgSO4 treatment
on seizure activity and microglial activation in a rat model of
severe preeclampsia (placental ischemia plus high cholesterol
diet) (Johnson et al., 2014), this is the first study to explore
whether chronic administration of MgSO4 can improve the
general characteristics of blood pressure, fetal demise, and CSF
cytokines in rats exposed to placental ischemia alone.
MATERIALS AND METHODS
Animals
Timed pregnant Sprague-Dawley (CD) rats were obtained from
Charles Rivers Laboratories and arrived at the Lab Animal
Facilities at the University of Mississippi Medical Center on
gestational day 11. All animal procedures were approved by the
Institutional Animal Care and Use Committee at the University
ofMississippiMedical Center. The rats weremaintained on a 12 h
light/ 12 h dark cycle and fed standard rodent chow and water ad
libitum.
Reduced Uterine Perfusion Pressure
(RUPP) Model of Placental Ischemia
To induce placental ischemia, silver clips were surgically inserted
around the abdominal aorta, below the kidneys, and each of the
uterine artery branches from the ovary on day 14 of gestation as
described previously. This procedure reduces blood flow to the
utero-placental unit by ∼40% in pregnant rats (Granger et al.,
2006). Animals were randomly assigned to normal pregnant (NP)
or placental ischemia (RUPP) groups.
Magnesium Sulfate Infusion
On gestational day 14, normal pregnant and placental ischemic
rats were implanted with mini-osmotic pumps to deliver
60mg/day MgSO4 (diluted in 0.9% saline solution) via the
intraperitoneal cavity. The resulting groups were NP (no
MgSO4), RUPP (no MgSO4), NP + MgSO4, and RUPP +
MgSO4. Using a commercially available kit (abcam, ab102506),
Mg levels in the plasma were 2.8 ± 0.6 mmol/L at the end of the
study (gestational day 19). Thus, therapeutic doses of Mg were
obtained.
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Measurement of Mean Arterial Pressure
(MAP) and Fetal Outcomes
On gestational day 18, rats were surgically instrumented with
carotid catheters for the measurement of mean arterial pressure.
On GD19, following at least 30min acclimation to the restrainer
cages, blood pressure was recorded for 30min. The mean arterial
pressure was then obtained using LabChart software. The uterine
horn was examined for determination of the number of live and
resorbed fetuses and the placentas and pups were removed and
weighed.
Collection of Cerebrospinal Fluid
On gestational day 19, rats were anesthetized using isoflurane
and secured on a stereotaxic frame and cerebrospinal fluid was
obtained via the cisterna magna using a butterfly needle and
syringe. CSF samples were flash frozen in liquid nitrogen and
stored at−80◦C until processing.
Determination of Brain Water Content
Following CSF collection, brains were harvested, cerebellum
dissected off, and cerebrum divided along the midline into two
hemispheres. Half of the brain was used for determination of
brain water content and was further separated into anterior
and posterior cerebrum by cutting along the middle cerebral
artery. Brain tissue anterior to the middle cerebral artery
was designated as anterior cerebrum while tissue posterior
to the middle cerebral artery (without the cerebellum) was
designated as posterior cerebrum. The brain regions were
weighed and then dried in an oven at 60◦C for 72 h, after
which dry weight was obtained. Brain water content was
then calculated as a percentage: [(wet weight-dry weight)/wet
weight]× 100.
Measurement of CSF Protein and
Albumin/Blood-CSF-Barrier Permeability
Cerebrospinal fluid (CSF) samples were thawed and
total protein was measured using the Bicinchoninic acid
(BCA) kit (ThermoFisher, 23225). Albumin content in
the CSF was measured using a Rat Albumin ELISA kit
(GenWay BioTech, GWB-1B2B4B) using a dilution factor
of 1:1000. Kits were run according to the manufacturer’s
directions.
Measurement of CSF Cytokine/Chemokine
Concentration
Cerebrospinal fluid (CSF) samples were thawed and assayed
using the rat cytokine/chemokine magnetic bead panel (Milliplex
MAP kit, EMD Millipore, RECYMAG65K27PMX) which
included 27 cytokines/chemokines. CSF samples were
assayed undiluted following manufacturer’s directions.
Cytokine/chemokine concentration was determined from a
standard curve generated for each analyte.
Statistical Analysis
Two-Way Analysis of Variance (group–NP and RUPP vs.
treatment–no MgSO4 or MgSO4 treated) was used to determine
differences amongst the groups followed by Fisher’s LSD post-
hoc test. Comparisons were considered statistically significant if
p < 0.05.
RESULTS
MgSO4 Has No Effect on Placental
Ischemia-Induced Increases in Blood
Pressure or Fetal Demise
The effects of placental ischemia and MgSO4 treatment on the
general characteristics of the rats are summarized in Table 1.
Placental ischemia resulted in a significant increase in MAP
and number of resorbed pups. MgSO4 treatment had no effect
on placental ischemia-induced increases in MAP or number of
resorbed pups. Placental ischemia led to a significant decrease
in the number of live fetuses and pup weight. MgSO4 had no
effect on placental ischemia-induced decreases in number of
live fetuses or pup weight. MgSO4 treatment reduced placenta
weight in the placental ischemic group. In normal pregnant
rats, MgSO4 treatment had no effect on any of the parameters
measured.
MgSO4 Prevented Placental
Ischemia-Induced Increases in Brain Water
Content
To determine whether MgSO4 prevents placental ischemia-
induced cerebral edema, brain water content was measured.
Anterior brain water content increased in response to placental
ischemia (Figure 1A) from 79.6± 0.1% in the pregnant group to
80.5 ± 0.3% (p < 0.01). MgSO4 prevented the increase in brain
water content in response to placental ischemia (79.8 ± 0.2%,
p = 0.01 compared to RUPP). In normal pregnant rats, MgSO4
treatment had no effect on brain water content (79.4 ± 0.2%).
There were no changes in brain water content in the posterior
cerebrum in response to placental ischemia or MgSO4 treatment
(Figure 1B).
MgSO4 Reduces Protein and Albumin
Concentrations in the Cerebrospinal Fluid
Placental ischemic rats had 5.2 ± 0.4 mg/mL protein compared
to 4.5 ± 0.4 mg/mL in the normal pregnant group (Figure 2A).
MgSO4 reduced protein content in the CSF in the placental
ischemic group to 3.6 ± 0.4 mg/mL; p = 0.03. MgSO4 treatment
had no effect on CSF protein concentration in the normal
pregnant group (3.6 ± 0.6 mg/mL). CSF albumin concentration
was 43.5 ± 6.2 µg/mL in the normal pregnant saline treated
group and 67.5 ± 17.7 µg/mL in the placental ischemic group
(p = 0.076; Figure 2B). MgSO4 significantly reduced albumin
concentration in the placental ischemic group (23.8± 4.0µg/mL;
p < 0.01) but had no effect on CSF albumin concentration
in normal pregnant rats (27.9 ± 5.4 µg/mL). Cerebrospinal
fluid albumin/protein ratio was calculated for each of the
animals (Figure 2C). The albumin/protein ratio in the normal
pregnant rats was 0.010 ± 0.001 compared to 0.013 ± 0.003
in the placental ischemia (RUPP) non-treated group. MgSO4
treatment significantly reduced the albumin/protein ratio in
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TABLE 1 | Summary of the general characteristics of pregnant rats.
Characteristics NP (N = 6) RUPP (N = 6) NP + MgSO4 (N = 9) RUPP + MgSO4 (N = 11)
MAP (mmHg) 102 ± 2 115 ± 3*† 100 ± 4 114 ± 2*†
No. of Live Pups 14 ± 0 7 ± 2*† 13 ± 1 6 ± 1*†
No. of Resorbed Pups 0 ± 0 6 ± 2*† 1 ± 0 7 ± 1*†
Pup Weight (g) 2.47 ± 0.06 2.24 ± 0.09* 2.27 ± 0.06 2.16 ± 0.05*
Placenta Weight (g) 0.47 ± 0.02 0.46 ± 0.01 0.46 ± 0.01 0.38 ± 0.02*†
*p < 0.05 vs. NP;
†
p < 0.05 vs. NP + MgSO4 group.
FIGURE 1 | Changes in brain water content in response to placental ischemia and MgSO4 treatment. (A) Placental ischemia (RUPP) increases anterior
cerebrum water content in pregnant rats while MgSO4 prevents the increase in brain water content in response to placental ischemia. No change in water content in:
(B) posterior cerebrum. Bars represent Mean ± SEM. *p < 0.05. N = 6–11 per group/treatment. NP, normal pregnant; RUPP, reduced uterine perfusion pressure.
the placental ischemic group to 0.006 ± 0.0001; p = 0.02
but had no effect in the normal pregnant group (0.007 ±
0.0000).
MgSO4 Reduces Cerebrospinal Fluid
Cytokine Levels
To determine whether MgSO4 leads to a reduction in
CSF cytokines, a multi-plex array was used to measure 27
different cytokine/chemokines in the CSF. The concentrations
are summarized in Table 2. Two-way analysis of variance
revealed significant increases in CSF eotaxin, IL-2, and IL-18
in response to placental ischemia. MgSO4 treatment resulted in
significant decreases in CSF eotaxin, fractalkine, GRO/KC/CINC,
interferon gamma, IL-2, IL-17, IL-18, MIP-2, and VEGF. MgSO4
treatment of normal pregnant rats had no effect on CSF
cytokines/chemokines except for MIP-2 where it was decreased.
DISCUSSION
The most widely used drug for the treatment of preeclampsia
patients with severe symptoms is magnesium sulfate. While
it is effective in preventing seizure activity, the mechanisms
by which it does so are not fully known. This study tested
the hypothesis that MgSO4 acts by protecting the brain from
edema formation and by reducing the levels of cytokines in the
cerebrospinal fluid. We found that while MgSO4 had no effect on
improving blood pressure or fetal outcomes following placental
ischemia, it reduced CSF protein and albumin concentration
as well as the level of cytokines in placental ischemic rats and
prevented placental ischemia-induced increases in brain water
content.
Numerous studies have shown a beneficial role for MgSO4
in preventing seizures; however, there have been reports of
no effects on other characteristic symptoms of preeclampsia.
For example, MgSO4 had no effect on angiogenic factors in
preeclampsia patients treated with MgSO4 (Vadnais et al.,
2012; Eshkoli et al., 2013). Importantly, MgSO4 was shown
to have no effect on reducing blood pressure in a rat
model of preeclampsia induced by lipopolysaccharide injection
(Huang et al., 2014) or the model of acute hypertension
in pregnant rats (Euser et al., 2008). The current study
showed no change in placental weight following placental
ischemia but a significant reduction in placental weight
following placental ischemia and MgSO4 treatment. We do
not know why MgSO4 would lead to reduced placental weight
following placental ischemia. Taken together, these studies,
along with the findings from the current study, support
the concept that MgSO4 improves the cerebral symptoms
but has minimal effects on other characteristic symptoms of
preeclampsia.
Preeclampsia is characterized by decreased cardiac output and
increased peripheral resistance, two factors that contribute to
the hypertension observed (Guy et al., 2016). The hemodynamic
changes in the placental ischemia model have been characterized
in a study by Sholook et al. (2007). In that study, the authors
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FIGURE 2 | Changes in cerebrospinal fluid protein and albumin
content. MgSO4 treatment decreases (A) CSF protein concentration, (B) CSF
albumin content, and (C) The ratio of albumin/protein. Bars represent Mean ±
SEM. *p < 0.05, **p < 0.01. N = 6–11 per group/treatment. NP, normal
pregnant; RUPP, reduced uterine perfusion pressure.
reported a 50–60% decrease in uteroplacental blood flow
with no change in blood flow to the kidney, liver, or brain,
and a decrease in blood flow to the heart. Like preeclampsia
patients, placental ischemic rats also demonstrated decreased
cardiac output and increased total peripheral resistance
(Sholook et al., 2007). Thus, the placental ischemic (RUPP)
model mimics the hemodynamic changes that occur in
preeclampsia.
Because (pre) eclampsia patients sometimes present with
various cerebrovascular abnormalities, including cerebral edema,
this study assessed changes in brain water content in rats
subjected to placental ischemia with MgSO4 treatment. As
shown previously, brain water content increased in response
to placental ischemia in the anterior cerebrum (Warrington
et al., 2014, 2015). Placental ischemia-induced increase in brain
water content was prevented by MgSO4 treatment. The increase
in brain water content in response to placental ischemia is
consistent with studies showing edema in preeclampsia patients
(Mitas and Rogulski, 2012), and the placental ischemic model
(Ryan et al., 2011; Warrington et al., 2014). It should be noted
that a recent paper reported decreased brain water content in the
posterior cerebrum of rats subjected to placental ischemia plus
a high cholesterol diet (Johnson et al., 2014). While this finding
appears contradictory to our current findings, the placental
ischemic model seems to be protected from posterior cerebral
edema and this study, along with previously published studies,
demonstrate that the anterior cerebrum is more susceptible
to cerebrovascular abnormalities following placental ischemia
(Warrington et al., 2014, 2015). Additionally a key difference
between the study by Johnson et al. (2014) and this one is that
the brain water content was measured following seizures in the
paper by Johnson et al. (2014) while the current study measured
brain water content following placental ischemia alone without
additional interventions.
While we do not know why the anterior cerebrum is more
susceptible to edema formation following placental ischemia, we
have shown that BBB permeability also increases in the anterior
cerebrum but not the posterior cerebrum (Warrington et al.,
2014) supporting the idea that increases in BBB permeability
in the anterior cerebrum contributes to the increased brain
water content. It is thought that vasogenic edema (through
BBB disruption) is the primary form of edema in preeclampsia
(Cipolla, 2007). We have not determined whether there are
ultrastructural changes at the BBB following placental ischemia;
however, we showed no changes in the expression of claudin-1,
occludin, or zonular occludens 1 in the anterior brain following
placental ischemia, suggesting that reductions in the expression
of tight junction proteins did not contribute to edema formation
following placental ischemia (Warrington et al., 2014).
It is possible that cytotoxic edema (cell swelling) could
contribute to anterior cerebral edema following placental
ischemia. Indeed, a recent study showed that traumatic brain
injury-induced cerebral edema is associated with increased
expression of aquaporin 4 (AQP4) and vasopressin 1a receptor
(Marmarou et al., 2014) and astrocytic swelling. We showed
previously that protein expression of AQP4 is increased in the
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TABLE 2 | Summary of cytokines/chemokines in the CSF of rats subjected to placental ischemia and/or MgSO4.
Cytokine/Chemokine NP (N = 7) RUPP (N = 6) NP + MgSO4 (N = 6) RUPP + MgSO4 (N = 7)
EGF (pg/mL) ND ND ND ND
Eotaxin 20.7 ± 2.9 31.3 ± 1.4* 17.0 ± 3.8‡ 19.7 ± 4.5‡
Fractalkine 36.2 ± 4.2 45.0 ± 3.4 31.3 ± 4.3‡ 29.8 ± 3.9‡
G-CSF 16.6 ± 1.7 15.6 ± 2.4 11.8 ± 2.3 17.5 ± 1.8
GM-CSF 184.5 ± 25.7 212.1 ± 37.0 159.9 ± 39.2 190.9 ± 34.1
GRO/KC/CINC 239.7 ± 30.6 243.9 ± 14.2 186.6 ± 32.0 163.05 ± 15.8*‡
Interferon Gamma 42.4 ± 6.5 61.7 ± 9.6 31.5 ± 7.9‡ 30.3 ± 8.6‡
Interleukin-10 12.4 ± 3.2 20.9 ± 4.5 10.9 ± 2.6 (5) 17.3 ± 5.9
Interleukin-12p70 ND 23.47 (2) ND ND
Interleukin-13 4.3 ± 2.0 (5) 7.8 ± 3.7 4.7 ± 2.6 (3) 6.1 ± 1.9 (5)
Interleukin-1 alpha 11.2 ± 1.0 (2) 7.3 ± 2.3 (5) 6.1 ± 2.1 (3) 6.4 ± 3.3 (3)
Interleukin-1 beta 25.1 ± 8.4 28.7 ± 5.2 14.8 ± 4.3 18.4 ± 5.1
Interleukin-2 40.7 ± 4.8 59.5 ± 9.5* 35.8 ± 5.2‡ 40.3 ± 5.7‡
Interleukin-4 12.7 ± 2.3 16.0 ± 3.7 13.3 ± 2.1 13.4 ± 2.1
Interleukin-5 25.0 ± 2.9 29.8 ± 5.2 19.8 ± 4.5 25.3 ± 3.4
Interleukin-6 343.2 ± 58.4 367.5 ± 83.3 301.8 ± 69.0 363.7 ± 54.9
Interleukin-17 12.9 ± 1.2 20.2 ± 3.7 11.9 ± 2.6‡ 12.2 ± 2.7‡
Interleukin-18 40.1 ± 5.1 60.9 ± 8.8* 40.2 ± 8.5 33.2 ± 6.3‡
IP-10 153.0 ± 30.4 137.1 ± 39.8 115.2 ± 28.3 109.2 ± 16.5‡
LIX/ CXCL5 ND 68.3 (1) ND ND
Leptin 86.5 ± 18.3 110.0 ± 17.9 63.3 ± 14.6 64.8 ± 12.4
MCP-1 143.0 ± 30.6 187.2 ± 33.5 127.1 ± 53.2 (4) 155.4 ± 14.8 (5)
MIP-1 alpha ND ND ND ND
MIP-2 93.6 ± 6.5 110.2 ± 11.2 63.7 ± 7.6*‡ 66.6 ± 7.4*‡
RANTES/ CCL5 33.3 ± 5.5 32.6 ± 6.8 22.8 ± 3.7 25.7 ± 3.9
TNF alpha 0.6 ± 0.2 (2) 1.3 ± 0.9 (2) 0.8 (1) 0.6 ± 0.2 (2)
VEGF 14.1 ± 1.6 18.3 ± 2.2 9.9 ± 1.5‡ 10.0 ± 1.7‡
*p < 0.05 vs. NP; ‡p < 0.05 vs. RUPP. Data represent mean ± SEM. The number in parenthesis represents the number of samples with detectable concentrations. ND, none
detected; EGF, epidermal growth factor; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte macrophage colony stimulating factor; GRO/KC/CINC, Growth-regulated
oncogene/keratinocyte chemoattractant/cytokine-induced neutrophil chemoattractant; IP-10, Interferon gamma-induced protein 10; LIX, Lipopolysaccharide-induced CXC chemokine;
MCP-1, monocyte chemotactic protein 1; MIP, macrophage inflammatory protein; RANTES, regulated on activation; normal T cell expressed and secreted; TNF, tumor necrosis factor;
VEGF, vascular endothelial growth factor. CSF cytokine data for NP vs. RUPP has been published previously (Warrington, 2015).
posterior cerebrum but unchanged in the anterior cerebrum.
We hypothesized that increased AQP4 protein expression in the
posterior cerebrum is an indicator of increased edema resolution.
Because we have not determined whether astrocyte morphology
changes in response to placental ischemia, we are unable to
determine whether the edema formation occurs as a result of
astrocyte swelling as well. Thus, MgSO4 could contribute to
resolution of placental ischemia-induced increases in brain water
content through changes in AQP4 and vasopressin receptor
expression by astrocytes, a question that will be answered in
future studies.
While the mechanisms by which MgSO4 exerts its effects
are not well understood, some studies have suggested potential
mechanisms ranging from vasodilation to reduced blood-brain
barrier permeability. There is evidence that in the cerebral
vasculature, MgSO4 acts as a vasodilator (Altura et al., 1987;
Perales et al., 1991; Belfort and Moise, 1992; Belfort et al., 1993;
Naidu et al., 1996; Euser and Cipolla, 2005), thus reducing
the increased pressure within the vasculature. MgSO4 may
offer neuroprotection through decreasing BBB permeability.
Indeed, MgSO4 has been shown to decrease BBB permeability
following traumatic brain injury (Esen et al., 2003), septic
encephalopathy (Esen et al., 2005), and hypoglycemia (Kaya
et al., 2001). MgSO4 has also been shown to reduce cerebral
edema formation following brain injury (Esen et al., 2003).
Furthermore, MgSO4 treatment reduced permeability to Evans
blue dye in pregnant rats subjected to acute hypertension (Euser
et al., 2008) in both anterior and posterior cerebrum. In the
current study, we did not measure changes in BBB permeability
to Evans blue dye or other similar molecules neither did we
measure changes in the ultrastructure of the tight junctions.
We, however, determined changes in brain water content to
determine cerebral edema formation, a consequence of increases
in BBB permeability. We report that MgSO4 reduces brain
water content possibly by reducing BBB permeability, previously
shown to be increased in the rat placental ischemic model of
preeclampsia (Warrington et al., 2014). Future studies will assess
whether placental ischemia induces damage to the choroidal
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ependymal cells or the endothelial tight junctions and whether
MgSO4 reverses that damage.
It is widely accepted that cytokines can influence brain
signaling and can contribute to changes in cerebrovascular
function as well as neuronal excitability. One potential
mechanism by which MgSO4 could have protective
effects in the brain could be through decreasing levels of
cytokines/chemokines. Both preeclampsia patients and the rat
model of placental ischemia are characterized by increased levels
of circulating and placental inflammatory cytokines. Importantly,
we recently showed that CSF levels of the cytokines/chemokines
eotaxin, IL-2, IL-17, and IL-18 are increased in the placental
ischemic rat (Warrington, 2015). We have extended these
findings to determine whether MgSO4 treatment would
lead to a reduction in levels of CSF cytokines/chemokines.
Our results indicate that 9 out of 27 cytokines/chemokines
(IL-17A, IL-18, eotaxin, fractalkine, interferon gamma, IL-2,
GRO/KC/CINC, macrophage inflammatory protein 2 (MIP-2),
and vascular endothelial growth factor (VEGF)) were reduced
by MgSO4 treatment in normal pregnant or placental ischemic
rats.
Increased levels of IL-17 (Martínez-García et al., 2011; Toldi
et al., 2011; Darmochwal-Kolarz et al., 2012) and IL-18 (Huang
et al., 2005; Seol et al., 2009; El-Kabarity and Naguib, 2011) have
been reported in preeclampsia patients. A direct role for IL-17
in mediating hypertension during pregnancy was demonstrated
using animal studies where infusion of IL-17 into the pregnant
rat increasedmean arterial pressure and oxidative stress (Dhillion
et al., 2012) while reducing IL-17 in placental ischemic rats
attenuates blood pressure and oxidative stress (Cornelius et al.,
2013). While there are no reports of changes in IL-17 levels
following eclamptic seizures, there are reports that IL-17 is
increased in the circulation of epilepsy patients in between
seizures or following seizures and IL-17 levels was correlated
with seizure frequency and severity in epilepsy patients (Mao
et al., 2013). CSF IL-17 levels were also elevated in patients
between seizure episodes (Mao et al., 2013) and were correlated
with glutamate levels and BBB disruption in a group of multiple
sclerosis patients (Kostic et al., 2014). Furthermore, IL-17 has
been shown to induce BBB disruption through the production
of reactive oxygen species and down-regulation of Occludin (a
tight junction protein) (Huppert et al., 2010). Thus, the current
findings support the hypothesis that MgSO4 offers protection
against BBB and blood-CSF-barrier permeability by decreasing
IL-17 levels in the CSF. Further studies are required to directly
test this hypothesis.
Eotaxin (CCL11) and fractalkine are chemoattractants.
Eotaxin is released by activated astrocytes and act on microglia
to promote glutamate-induced neurotoxicity (Parajuli et al.,
2015) while fractalkine is released from neurons and glia and
act mainly on microglia. While there are no studies reporting
changes in eotaxin levels during preeclampsia, the current
study shows increased CSF eotaxin following placental ischemia
and reduced levels following MgSO4 treatment. It is possible
that placental ischemia-induced increases in CSF eotaxin may
indicate increased glutamate activity and neurotoxicity and the
MgSO4 protection against seizure may act through reduced
eotaxin levels. Future studies will determine whether placental
ischemia is associated with increased glutamate signaling. A
recent study showed that placental fractalkine levels are increased
in severe early preeclampsia patients (Siwetz et al., 2015). Because
fractalkine can reduce GABAergic function in pyramidal neurons
in patients withmesial temporal lobe epilepsy (Roseti et al., 2013),
it is possible thatMgSO4 may exert its anti-seizure effects through
reduced fractalkine levels. This possibility was not tested in the
current study and will be the subject of future studies.
The pro-inflammatory cytokine, interferon gamma (Ozkan
et al., 2014; Yang et al., 2014) has been reported to be
increased in the circulation (plasma and serum) of preeclampsia
patients. Additionally, patients with temporal lobe epilepsy
have also been reported to have increased levels of interferon
gamma (Vieira et al., 2016). However, the effects of MgSO4
treatment on these cytokines have not been assessed. The
current study shows that interferon gamma is reduced following
MgSO4 treatment, thereby reducing the inflammatory status
and offering neuroprotection. There are no studies showing a
relationship between MIP-2 levels in preeclampsia, eclampsia,
or epileptic patients. However, the finding that MIP-2 is
reduced following MgSO4 treatment suggests that MIP-2 may
be involved in increased seizure susceptibility and its role in
mediating increased seizure susceptibility will be explored in
future studies.
We found a significant reduction in cerebrospinal fluid VEGF
levels following MgSO4 treatment but no change with placental
ischemia alone. VEGF is a pro-angiogenic factor, released in
conditions of tissue hypoxia (Pugh and Ratcliffe, 2003; Liao
and Johnson, 2007; Denko, 2008). VEGF is also associated
with increased vascular permeability and has been shown to
be important during cerebral edema formation (Huang et al.,
2016). Further studies are required to assess whether decreases
in CSF VEGF after chronic MgSO4 treatment could indicate
reduced tissue levels of VEGF, resolution of tissue hypoxia,
and whether VEGF is important for placental ischemia-induced
cerebral edema formation, and MgSO4-induced resolution of
cerebral edema. While one study showed increases in circulating
TNFα in a rat model of preeclampsia and decreases in
TNFα following MgSO4 treatment (Huang et al., 2014), we
found no differences in the level of CSF TNFα following
placental ischemia or MgSO4 treatment possibly due to the
fact that the majority of the samples were below detectable
range.
The recently described glymphatic system describes a role for
the CSF in collecting products from the extracellular space into
the CSF (Iliff and Nedergaard, 2013; Mendelsohn and Larrick,
2013; Plog et al., 2015) by neuroglia. Indeed, a recent study
demonstrated increased levels of activated microglia in placental
ischemic rats fed a high cholesterol diet and that MgSO4 reverses
the increase in activated microglia (Johnson et al., 2014). While
the current study is unable to establish the source of the CSF
cytokines/chemokines, the increases in CSF cytokines following
placental ischemia could indicate increased inflammation at the
tissue level and increased numbers of activated microglia while
the reduction in CSF cytokines followingMgSO4 treatment could
indicate reduced tissue inflammation and reduced number of
activated microglia. This will be tested in future studies. It is
also possible that increases in CSF cytokines may represent
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increased clearance of tissue inflammation. Therefore, changes in
the glymphatic system following placental ischemia and MgSO4
treatment will be determined in future studies.
The current study represents a hypothesis generating study
that presents several potential mechanisms by which MgSO4
offers neuroprotection following placental ischemia, relevant
for the clinical condition of preeclampsia. We showed that
MgSO4 prevents placental ischemia-induced increases in brain
water content and CSF cytokines/chemokines. However, whether
the observed differences translate to neuroprotection is not
known. Based on our findings, MgSO4 therapy seems to
preferentially protect the brain from cerebrovascular insults in
a model of placental ischemia that closely mimics the clinical
condition of (pre) eclampsia. Specifically,MgSO4 protects against
cerebral edema formation and CSF inflammation and may be
a mechanism for the prevention of seizures or the progression
from preeclampsia to eclampsia. Because this study utilized the
chronic infusion of MgSO4 (5 days) that commenced from the
initiation of placental ischemia, we are unable to discuss whether
acute treatment will have similar effects. Also, whether chronic
infusion of MgSO4 can lower seizure threshold in rats subjected
to placental ischemia alone is not known.
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